Explorer les evidences

Palier Gold : evidences validées mécaniquement, avec leur source primaire.

8 823 evidences · page 72 / 353

45,3 %The prevalence of onychomycosis among diabetic subjects was 45.3%.

Nigeriaonychomycosispublié 2024West African journal of medicinePubMeddocument de 6 observations

67,2 %In the MEND case-control study, 67.2% of Nigerian breast cancer cases were grade 2.

Nigeriacancer du seinpublié 2026Breast cancer research and treatmentPubMeddocument de 10 observations

4 %An impaired relaxation pattern was observed in 4.0% of the HIV group.

NigeriaVIH/sidapublié 2022BMC pediatricsPubMeddocument de 6 observations

2 000 per_μLAsexual parasite densities were highest in the northern geopolitical zones (geometric means > 2000 μL).

Nigeriapaludismeobservé 2018publié 2023Scientific reportsPubMeddocument de 3 observations

27 %The high diversity microbiota, Community State Type IV-B, was the most prevalent in HIV-positive women (27% at baseline, 35% at follow-up).

Nigeriahigh diversity microbiota, Community State Type IV-Bpublié 2020Scientific reportsPubMeddocument de 6 observations

0 %Uptake of pap smear was 0.0% in the intervention group at baseline.

Nigeriacancer du col de l'utéruspublié 2022BMC women's healthPubMeddocument de 5 observations

81 %Cross-resistance to at least one of the newer NNRTIs—doravirine, etravirine or rilpivirine—was predicted in 81% of participants with HIV-1 who had failed first-line ART in Nigeria.

NigeriaVIH/sidapublié 2022The Journal of antimicrobial chemotherapyPubMeddocument de 9 observations

9,6 %The prevalence of diabetes mellitus among market traders in Jos North Local Government Area of Plateau State was 9.6%.

Nigeriadiabète (non précisé)publié 2021Nigerian journal of clinical practicePubMeddocument de 9 observations

16,9 %Out of 144 cervical samples, 24 were positive for HPV16 by PCR, representing a molecular prevalence rate of 16.9%.

Nigeriainfection à HPVpublié 2022African health sciencesPubMeddocument de 2 observations

7,6 %In a cross-sectional study of 405 Nigerian children, 7.6% were homozygous for alpha+-thalassaemia.

Nigeriadrépanocytosepublié 2001Tropical medicine & international health : TM & IHeurope_pmcdocument de 8 observations

11 daysSD Bioline MPT64 achieved a shorter median time to identification of MTBC at 11 days compared to 26 days by the conventional method.

Nigeriatuberculosepublié 2021Journal of immunoassay & immunochemistryPubMeddocument de 6 observations

16 %Glucose-6-phosphate dehydrogenase deficiency was present in 16% of hemizygous males (94/603) and 4% of homozygous females (22/598) among enrolled patients.

Nigeriaglucose-6-phosphate dehydrogenase deficiencypublié 2009PLoS ONEOpenAlexdocument de 9 observationsDOI 10.1371/journal.pone.0006682

5 %The likelihood of major depressive disorder increased by 5% for every point reduction in social support scores.

Nigeriamajor depressive disorderpublié 2022AIDS carePubMeddocument de 3 observations

68 %In a single-arm trial, self-reported adherence ≥90% among youth with HIV in Nigeria increased to 68% at 48 weeks (P = 0.031) compared with baseline.

NigeriaVIH/sidapublié 2021Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 12 observations

6,2 %Coexistence of hypertension and impaired fasting capillary glucose (IFCG) was prevalent among 6.2% of rural adolescents aged 10–19 years in southeast Nigeria.

Nigeriahypertension and impaired fasting capillary glucosepublié 2021BMJ openPubMeddocument de 5 observations

Malaria incidence and mortality data were used from the Malaria Atlas Project.

Nigeriapaludismepublié 2026Malaria journalPubMeddocument de 8 observations

81,3 %Among 370 HIV-positive individuals in Akwa Ibom state, Nigeria, 81.3% were not virally suppressed in 2017.

NigeriaVIH/sidaobservé 2017publié 2021Journal of the International AIDS SocietyPubMeddocument de 9 observations

42,5 %Peripheral arterial disease occurred in 42.5% of 400 type 2 diabetes participants in a tertiary hospital in south west Nigeria.

Nigeriadiabète de type 2 · Peripheral arterial diseasepublié 2022The Pan African medical journalPubMeddocument de 16 observations

0 per_62Lassa-fever-specific IgM was detected in 0 out of 62 monkey serum samples collected between August 2015 and December 2017 in Southern Nigeria.

Nigeriafièvre de Lassaobservé August 2015 to December 2017publié 2019Journal of epidemiology and global healtheurope_pmcdocument de 3 observations

7,2 %Forty-nine (7.2%) of 676 tuberculosis patients at the TB DOTS clinic of Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, from January 2017 to December 2021 had unknown HIV status.

NigeriaVIH/sidaobservé 2017 to 2021publié 2024West African journal of medicinePubMeddocument de 14 observations

69,1 %Hydroxyurea dose escalation beyond 20 mg/kg/day was required to attain significant reductions in the time-averaged mean of maximal velocities in 69.1% of the cases.

Nigeriadrépanocytosepublié 2021Pediatric blood & cancerPubMeddocument de 5 observations

150 000 infantsAn estimated 150,000 infants with sickle cell anemia are born annually in Nigeria.

Nigeriadrépanocytosepublié 2021Pediatric neurologyPubMeddocument de 4 observations

63,5 %63.5% of the participants showed good knowledge of cervical cancer screening and vaccination.

Nigeriacancer du col de l'utéruspublié 2023BMC women's healthPubMeddocument de 7 observations

5 %Among pregnant women in Nigeria, the probability of being in the worst-case scenario (fewer than four antenatal care visits and fewer than three intermittent preventive treatment with sulfadoxine-pyrimethamine doses) was 5% among the wealthiest women with higher education.

Nigeriapaludismeobservé 2018publié 2026Malaria journalPubMeddocument de 9 observations

591 103 335 USDThe funding shortfall for national malaria interventions in Nigeria from 2018 to 2020 was $591,103,335, or 52.7% of the needs.

Nigeriapaludismeobservé 2018-2020publié 2023A Conceptual Framework on the Role of Backward Integration in Sustainable Access to Malarieurope_pmcdocument de 9 observationsDOI 10.21203/rs.3.rs-2963622/v1

Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.